LONDON, June 12, 2015 /PRNewswire/ --

Broadened diagnostic criteria and growing adult prevalence to drive market growth, despite patent expirations, says  GBI Research.

Analysis from business intelligence provider GBI Research - ADHD Therapeutics to 2020 - says that the global Attention-Deficit Hyperactivity Disorder (ADHD) treatment market is predicted to rise in value from $11.5 billion in 2013 to $13.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 2.2%.

There are 68 therapies in active development in the ADHD pipeline and, while many share mechanisms of action with marketed therapies, some also have different dosing strategies to improve treatment compliance. Eight late-stage therapies are anticipated to reach the market during the forecast period, with differing clinical and commercial potential.

For a complimentary sample of this research, please visit the GBI Research website.

Current treatment regimens, primarily psychostimulants, aim to reduce or prevent symptoms of hyperactivity, inattention and impulsivity to improve quality of life. While there is a significant need for new ADHD therapies, development is limited by the current clinical understanding of the disease.

ADHD has a global prevalence of approximately 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in adults has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers. 

Senior Analyst Josh Libberton: "The fifth edition of The Diagnostic and Statistical Manual of Mental Disorders, published in 2013, broadened the diagnostic criteria for ADHD, recognizing that impairment from symptoms of the disorder may develop in later life.

"These developments herald the final acceptance of adult ADHD in a clinical setting and mean that many people who previously met the 'partial remission' criteria will now meet the full criteria, leading to an increase in diagnosis. However, the continuing reluctance of many patients to seek treatment for mental health conditions will be a barrier to ADHD diagnosis rates and consequently to further market growth."

Key Findings Include:

• While marketed therapies treat ADHD symptoms, they are not curative; fundamental causes of the disease remain unknown
• A relatively small pipeline focuses on established mechanisms of action, as a limited understanding of disease pathophysiology restricts innovative development
• There have been 13 licensing deals and eight co-development deals pertaining to ADHD products since 2006

Click here to find out how this analysis could benefit your business.

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For more information, please contact GBI Research on: +44-1204-543-533

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook  |LinkedIn  |Twitter

SOURCE GBI Research